TriSalus Life Sciences (NASDAQ:TLSI) Director Purchases 50,000 Shares of Company Stock

Key Points

  • Director Mats Wahlstrom purchased 50,000 shares at $2.24 each, spending $112,000 and increasing his stake by 33.89% to 197,555 shares.
  • TriSalus reported a quarterly loss of $0.15 per share, missing the $0.13 loss estimate; revenue of $12.88 million also fell short of the $14.02 million consensus.
  • Analysts hold a consensus “Moderate Buy” rating, with an average price target of $9.20, though the stock was reported down 6.6% and trading near its one-year low.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) Director Mats Wahlstrom bought 50,000 shares of the business's stock in a transaction on Thursday, November 12th. The shares were acquired at an average price of $2.24 per share, for a total transaction of $112,000.00. Following the completion of the transaction, the director owned 197,555 shares in the company, valued at approximately $442,523.20. This trade represents a 33.89% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

TriSalus Life Sciences Trading Down 6.6%

Shares of NASDAQ TLSI opened at $2.27 on Tuesday. The company has a quick ratio of 4.97, a current ratio of 4.22 and a debt-to-equity ratio of 47.60. TriSalus Life Sciences, Inc. has a 1 year low of $2.16 and a 1 year high of $7.95. The firm's 50-day moving average is $3.99 and its 200-day moving average is $4.28.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $12.88 million for the quarter, compared to the consensus estimate of $14.02 million. Equities analysts expect that TriSalus Life Sciences, Inc. will post -0.62 EPS for the current year.

Analyst Ratings Changes




TLSI has been the topic of a number of recent research reports. HC Wainwright reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 11th. Guggenheim set a $12.00 price target on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $7.00 to $4.00 and set a "buy" rating on the stock in a research report on Tuesday, November 10th. Citigroup reaffirmed a "buy" rating on shares of TriSalus Life Sciences in a research note on Tuesday, November 10th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $9.20.

Read Our Latest Stock Analysis on TLSI

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently modified their holdings of the company. Cura Wealth Advisors LLC acquired a new position in TriSalus Life Sciences during the second quarter valued at approximately $36,000. Russell Investments Group Ltd. bought a new stake in TriSalus Life Sciences in the third quarter valued at approximately $68,000. Provenance Wealth Advisors LLC acquired a new stake in TriSalus Life Sciences in the third quarter worth $94,000. Renaissance Technologies LLC acquired a new stake in TriSalus Life Sciences in the first quarter worth $124,000. Finally, Deutsche Bank AG bought a new position in shares of TriSalus Life Sciences during the second quarter worth $221,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company's TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

Recommended Stories

Insider Buying and Selling by Quarter for TriSalus Life Sciences (NASDAQ:TLSI)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at TriSalus Life Sciences?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for TriSalus Life Sciences and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles